NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology. This nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are artificial Antigen Presenting Cells (aAPC) that present antigens to T cells eliciting a highly targeted therapy driven by the patient’s immune system. These aAPC can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient’s body.
Location: United States, Maryland, Gaithersburg
Member count: 51-200
Total raised: $23M
Founded date: 2011
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 02.01.2018 | - | $23M | - | citybizlis... |
Mentions in press and media 8
| Date | Title | Description | Category | Author | Source |
| 19.02.2021 | Shorties R... | More workers in D.C. can now g... | - | - | technical.... |
| 29.04.2019 | MMRF Ventu... | GAITHERSBURG, Md. and NORWALK,... | - | - | citybizlis... |
| 08.08.2018 | SQZ Biotec... | The company will initially app... | - | - | medcitynew... |
| 02.01.2018 | NexImmune ... | GAITHERSBURG, Md., Jan. 02, 20... | - | - | citybizlis... |
| 21.07.2014 | NexImmune ... | GAITHERSBURG, MD, Early stag... | - | - | vcnewsdail... |
| 09.02.2012 | Artificial... | “The big caveat is that all of... | - | - | medcitynew... |
| - | Artificial... | A new treatment for cancer tha... | - | - | medcitynew... |
| - | SQZ Biotec... | A company developing cell ther... | - | - | medcitynew... |